Top Markets
#1 Bitway Bitway +55.02%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +41.19%
#3 Starpower Starpower +37.49%
#4 Pons Pons +34.50%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.80%
#6 aelf aelf +22.66%
#7 SkyAI SkyAI +19.87%
#8 Ocean Protocol Ocean Protocol +18.26%
#9 OpenEden OpenEden +18.13%
#10 Mubarak Mubarak +15.20%
Coin of the day
Bitway Bitway
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
SynCore Biotechnology Co.,Ltd SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192
Peringkat dalam Saham #29318
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Harga Saham
$0.62008105
Terakhir disinkronkan: 2026-08-18
Kapitalisasi Pasar
$21.81M
Perubahan (1 hari)
0.26%
Perubahan (1 tahun)
-31.95%
Negara
TW
Perdagangan SynCore Biotechnology Co.,Ltd (4192)

Kategori

Healthcare
Laba untuk SynCore Biotechnology Co.,Ltd (4192)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari SynCore Biotechnology Co.,Ltd, laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk SynCore Biotechnology Co.,Ltd dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH